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A wind of change characterizes epilepsy research eﬀorts. The traditional approach, based on a neurocentric view of seizure
generation, promoted understanding of the neuronal mechanisms of seizures; this resulted in the development of potent anti-
epileptic drugs (AEDs). The fact that a signiﬁcant number of individuals with epilepsy still fail to respond to available AEDs
restates the need for an alternative approach. Blood-brain barrier (BBB) dysfunction is an important etiological player in seizure
disorders, and combination therapies utilizing an AED in conjunction with a “cerebrovascular” drug could be used to control
seizures more eﬀectively than AED therapy alone. The fact that the BBB plays an etiologic role in other neurological diseases
will be discussed in the context of a more “holistic” approach to the patient with epilepsy, where comorbidity variables are also
encompassed by drug therapy.
1.Introduction
The blood-brain barrier (BBB) is a system of capillary
endothelial cells that protects the brain from harmful
substances present in the blood stream, while supplying the
brain with the nutrients required for proper function [1–3].
The capillary endothelium is characterized by the pres-
ence of tight junctions, lack of fenestrations, and minimal
pinocytotic vesicles. In particular, tight junctions between
endothelial cells form a barrier, which selectively excludes
most blood-borne substances from entering the brain, pro-
tecting it from systemic inﬂuences. The BBB is anatomically
and functionally associated with brain parenchymal cells.
The distance between a BBB capillary and neurons is of
few micrometers while the overall surface of exchange
between the BBB and the brain parenchyma reaches 20m2
in the adult human brain [4]. In short, the extent and
complexity of the cerebrovascular interface together with
the anatomical proximity of BBB vessels and neurons are
highly suggestive of an active role in brain disease. In
addition to the structural integrity of the BBB, there exists
an enzymatic surveillance system that metabolizes drugs and
other compounds bypassing the structural barrier. Recently,
as t r o n ge ﬀect of these enzymes on antiepileptic drugs
(AED) metabolism has been shown in human epileptic brain
[5].
Failure of the BBB has been traditionally considered the
result of brain diseases (e.g., brain tumors, seizures, central
nervous systeminfections, multiple sclerosis).As aresult,the
potentialforatherapeuticapproachtorestoreBBBfunctions
has been overlooked for a more traditional neuronal take
of brain pharmacology. The latter approach has been only
partially successful, as evidenced by the persistent clinical
burden represented by drug-resistant brain diseases [6, 7].
Most animal models of neurological disorders are based on
the fact that brain neurons are the sole origin of the disorder
and therefore the chief targets, while a possible role for the
cerebral vasculature is often overlooked (Figure 1).2 Cardiovascular Psychiatry and Neurology
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Figure 1: Seizure generation based on cerebrovascular events. Traditionally, the main and leading hypothesis to explain seizures consisted
of abnormal neuronal wiring and excitability. While evidence of this is undisputed, the alternative/complementary hypothesis also adds to
the mix pre-existing leakage of the BBB, which generates a decrease in seizure threshold. According to this hypothesis BBB leakage decreases
seizure threshold independent of the fact that such leakage is associated with or a result of the seizure itself (blue versus red idealized traces).
In other words, and based on the results by Friedman’s Group, traumatically induced BBB disruption (BBBD) lowers seizure threshold.
Others (e.g., Marchi et al.) have shown that BBBD alone is suﬃcient to provoke a seizure in a nonepileptic animal. While the contribution
of BBB dysfunction to seizures has been demonstrated, the exact mechanisms (e.g., brain entry of peripherally circulating molecules, yellow
dots in the cartoon) remain unclear.
2.Astrocytesandthe Blood-Brain Barrier
Glial cells are numerically the predominant cell type in the
brain, and the glial/neuron ratio increases dramatically with
brain complexity and size [8]. Astrocytes, a speciﬁc subtype
of glial cells play an important role in regulating cerebral
ion homeostasis, transmitter regulation, maintenance of
the blood-brain barrier (BBB), and structural, as well as
metabolic, support of neuronal cells, for example, by pro-
viding the glucose-lactate shuttle [8, 9]. At the vascular level,
astrocytes extend larger processes also known as “end-feet”
whose terminations cover 99% of the abluminal vascular
surface of capillaries, arterioles, and venules present in the
cerebrovascular network. At the brain microcapillary level,
these cells become one of the main building blocks of the
BBB, a highly specialized dynamic and functional interface
between the blood and the brain that plays a primary role
in controlling and modulating the homeostasis of the central
nervous system (CNS).
3. Blood-Brain BarrierFunction:Unless You
CanMeasure,You CannotStudy It
One of the problems of BBB research has been the lack
of reliable methods to measure BBB intactness [10, 11].
“Opening” of the BBB provides molecules normally present
in blood with open passage into the CNS. Proteins normally
p r e s e n ti nb l o o da r ef r e et od i ﬀuse into the CNS, and
in turn, molecules and protein normally present in high
concentrations in the CNS are free to diﬀuse into the
blood. These peripheral markers of BBB opening can be
detected in the blood in order to evaluate the permeability
characteristics of the BBB at any given time. In brief, such
markers should have low or undetectable plasma levels in
normal subjects and have a higher concentration in the CSF
than in plasma [10, 11]. These proteins should be normally
blocked by the BBB and exhibit ﬂux across the BBB during
barrier damage. Several proteins, including S100β,n e u r o n -
speciﬁc enolase (NSE), and glial ﬁbrillary acidic protein
(GFAP), have been evaluated for this purpose, but only
S100βmeetsalltheabove-mentionedcharacteristics[10,11].
The fact that serum S100β can be used as marker of BBB
integrity is not necessarily in disagreement with the notion
that S100β is also a marker of brain damage, since both
phenomena (BBB failure and brain damage) are temporally
and topographically associated. In general, changes in S100β
correlatewellwithradiologicalindexesofBBBfunction,such
as signal changes on MRI [12, 13].
These methodological aspects of BBB measurements are
crucial to our understanding of the relative contribution of
the BBB to seizure development. Seizures and epilepsy are
commonly observed in conjunction with stroke, traumatic
brain injury and CNS infections, all conditions known to
result in compromised BBB function. A point of debate isCardiovascular Psychiatry and Neurology 3
whether the compromised integrity of the BBB may be a
prodromic component of the etiology of epilepsy secondary
to such pathologies (Figure 1). In support of this hypothesis
is the fact that BBB damage after acute head trauma is a
well-known pathologic ﬁnding in both animal and human
studies. BBB disruption may persist for weeks to years after
the injury and may colocalize with the area of abnormal
EEG activity [14–16]. The increased interest in osmotic
opening of the BBB as a viable mechanism of increased
drug delivery to the brain provides an opportunity to
explore the connection between BBB opening and seizures
in a controlled clinical environment. Osmotic opening of
the BBB by vascular infusion of a hyperosmolar bolus of
mannitol is mediated by vasodilatation and shrinkage of
capillary endothelial cells. Cell shrinkage results in widening
of the interendothelial tight junctions to an estimated radius
of 200 ˚ A[ 17]. The permeability eﬀect is largely reversed
within minutes. In rodents, porcine and humans loss of
BBB integrity by intra-arterial hyperosmotic mannitol has
been shown to rapidly lead to EEG changes consistent with
epileptic seizures [18–20], that is, spike/wave complexes
interspersed with decreased EEG voltage. These studies
demonstrate a correlation between the extent of acute BBB
openings, as evaluated by imaging and serum S100β levels,
and development of seizures.
Another example of S100β application is shown in
Figure 2(a). We measured S100β serum levels to establish
a temporal relation between a BBB score and seizure
development. We collected blood from patients with drug-
resistant epilepsy before, during, and immediately after an
ictal event. Patients were continuously monitored by EEG.
WefoundthatS100βserumlevelswereelevatedatthetimeof
seizures compared to postictal, interictal levels (Figure 2(a)).
The latter ﬁnding has several implications and represents
the ﬁrst attempt to monitor BBB status during a speciﬁc
interictal-ictal-interictal transition.
A profound remodeling of the cerebral vasculature
associated with leakage and extravasation of serum proteins,
consequently with spontaneous seizures, is observed in
rodent models of temporal lobe epilepsy. Moreover, it was
recently demonstrated that angiogenesis occurs in human
TLE (as well as in rodent models of TLE) as a consequence of
seizures[22].InparticularupregulationofVEGFinneurons,
accompanied by an increase in vascular density, has been
described after acute, short- or long-lasting seizures. Once
initiated, the angiogenic processes increase progressively,
even in the absence of seizure activity, as observed during
the latent period (e.g., in pilocarpine-treated rats), or after
single short seizures induced by electro-convulsive shock.
Conversely, it has also been repeatedly shown that BBB
leakage promotes seizures or epileptogenesis [19, 23, 24].
Whatever the temporal relationship between BBB leakage
andseizures,itisclearthattheepilepticbrainischaracterized
by an abnormal blood-brain interface (Figure 1).
Controversial is the use of imaging techniques to detect
BBB damage. The presence of brain edema can be evaluated
by MRI. Speciﬁcally, structural changes at a cellular level
can be assessed by diﬀusion-weighted imaging (DWI),
which calculates the extent of passive water motion or
diﬀusivity (apparent diﬀusion coeﬃcient, ADC). Curiously,
contradictory data have been obtained when evaluating the
changes in brain water perfusion in rodent models and
in patients with epilepsy [25–28]. DWI analysis in animal
studies has demonstrated an early and transient decrease
of water diﬀusivity during provoked status epilepticus or
sustained seizures. Peri-ictal and postictal human studies,
using DWI or diﬀusion tensor imaging (DTI), have also
shown transiently decreased local diﬀusivity in some cases
[25–28].
4. The Blood-Brain Barrier andIctogenesis
While epilepsies aﬀect approximately 1% of the population,
seizures may occur sporadically in a much larger number
of subjects [29]. Historically, a neurocentric philosophy has
dominated the study of epilepsy and seizures, and only
recently the research ﬁeld has considered the fact that the
cerebral vasculature is in fact intimately involved in the
maintenance of proper neuronal activity and pathogenesis
of seizures (Figure 1). BBB damage can occur as result of
pathological events initiated “outside the brain,” such as
stroke, peripheral inﬂammation, iatrogenic vascular manip-
ulations, hypertension, heat, and blood hyperosmolarity.
The latter are clinically associated with adverse neurological
consequences such as cognitive impairment, psychiatric
disturbances, and seizures. Evidence indicates that, within
the periphery-brain axis, the BBB represents the key player
in translating peripheral/vascular pathological events into
a neuronal pathological signal, such as seizures. Perhaps
the ﬁrst question we must ask relates to the timing of
BBB damage in relation to seizure occurrence: which comes
ﬁrst? Does BBB damage initiate seizures or vice versa? In
experimental models of epilepsy, seizures are commonly
induced by manipulation of neuronal receptors or by a
kindling process. Under these conditions, neuronal death,
reactive gliosis, and increased BBB permeability have been
predominantly considered as the consequences of seizures
[30]. This approach, and the subsequent interpretation of
data, has detracted importance from the etiological role of
the BBB in epilepsies and, for the most part, has impeded
development of alternative pharmacological targets. Seizures
are a result of a shift in the normal balance of excitation
and inhibition within the brain. Given the numerous players
controlling neuronal activity, it is not surprising that many
diﬀe r e n tw a y se x i s tt op e rt u r bt h i sn o r m a lb a l a n c e ,t h u st r i g -
gering seizures. Extravasation of serum albumin in the brain
parenchyma was proposed as a mechanism contributing
to ictogenesis and epileptogenesis in condition of damaged
BBB. Direct brain exposure to serum albumin is associated
with downregulation of inward-rectifying potassium (Kir
4.1) channels in astrocytes, resulting in reduced buﬀering
capacity [31].
An important corollary of the BBB-centric hypothesis
is the fact that interictal-to-ictal transitions may be caused
by cycles of BBB openings. Patients with epilepsy have
seizures intermittently, and, depending on the underlying
cause, many patients are seizure-free for months. The
sporadic appearance of seizures implies that there are4 Cardiovascular Psychiatry and Neurology
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Figure 2: (a) Evidence in support of a link between blood-brain barrier failure and seizures in human subjects shows the rational for the use
of serum S100β as a surrogate marker of BBBD. Extensive literature cited in this paper explains in further detail how this test is interpreted.
The data presented herein refers to preliminary ﬁndings obtained in a cohort of subjects in the EEG monitoring unit. These subjects were
continuously monitored for EEG changes suggestive of seizures. Serum samples were taken interictally, ictally, while another sample was
taken postictally after approximately 3 hours. Note the increase of ictal S100β as indication of blood-brain barrier opening in these subjects.
(b) Eﬃcacy of glucocorticosteroids in a cohort of pediatric drug resistant epileptic subjects. The etiology of seizures that responded to
steroids is shown in the pie chart in B1, while B2 shows the eﬃcacy of anti-inﬂammatory treatment. (c) Note that discrete regions of the
brain appear to have developed abnormal signal on contrast enhanced (Gd) or FLAIR sequences (see also [21]). Note that, in the MRI scans
shown, the eﬃcacy of steroids on seizures was paralleled by changes possibly associated with improved blood-brain barrier function (n = 2
patients).
precipitating factors inducing seizures in these patients.
Seizure precipitating factors include psychological or phys-
ical stress, sleep deprivation, hormonal changes associated
with the menstrual cycle, or exposure to toxic substances
and certain medications [29]. All of these factors have been
shown to be associated with compromised BBB permeability
[30]. Severe head trauma is associated with a damaged
BBB and with high risk of epilepsy [15]. The propensity of
severe trauma leading to development of epilepsy suggests
that brain injury results in long-lasting, pathologic changes
in the brain that change a normal neural network into a
hyperexcitable one. Furthermore, it is reasonable to predict
that BBB damage could be suﬃcient to turn a “silent” brain
malformation into an active one, allowing for the develop-
ment of recurrent seizures and drug resistance. Pre-existing
abnormalities in cortical development may contribute to theCardiovascular Psychiatry and Neurology 5
occurrence of seizures in response to a vascular challenge
(two-hit hypothesis, Figure 1).
5.InterplaybetweenSeizures,Blood-Brain
Barrier,andWhiteBloodCells
Experimental evidence has indicated a role of brain inﬂam-
mation in epilepsy [32]. It is important to underscore that
any inﬂammatory process, either of peripheral or brain
origin, includes early vascular damage, fundamental to
the propagation and maintenance of inﬂammation. Thus,
inﬂammatory process follows traditional pathophysiological
sequelae and is accompanied by dilation and increased per-
meability of blood vessels. It is surprising that, when dealing
with seizure disorders, this deﬁnition is often forgotten and
parenchymal cells are considered to be sole players in the
inﬂammatory process.
As stated above, experimental evidence supports the role
of intravascular inﬂammation in seizure disorders. Recently,
the involvement of circulating immune cells, their interac-
tion with the BBB, and seizure propensity have been recently
investigated [33]. Concordant data have been obtained using
models of peripheral inﬂammation, such as experimental
colitis, or the systemic administration of the cholinergic
agonist pilocarpine [34–37]. Activation of circulating white
blood cells (WBCs) was observed in animals prior to the
development of seizures. In particular, pilocarpine induced
acute intravascular proinﬂammatory changes leading to BBB
leakage. In addition, loss of BBB function could be triggered
by systemic proinﬂammatory events occurring in response
to seizure activity and activation of the hypothalamic-
pituitary-adrenal axis. Recently, a profound postictal change
in the immune cell composition of peripheral blood in
epileptics was reported [38]. In particular, NK and T
CD8+ cell count was elevated. This is suggestive of the
involvement of the immune axis mediated by the mesial-
sympathetic connections. Based on this evidence, one may
envision a model where bidirectional ﬂux of neuroimmune
information travels from and to the CNS to involve systemic
organs. Departure from this equilibrium may favor seizures.
An additional piece to the puzzle is whether or not
transmigration of WBCs occurs during epileptogenesis or
acute and chronic seizures. While studies have demonstrated
the proseizure eﬀect of BBB-WBCs interaction, it is not
clear whether WBCs need to invade the brain to pro-
duce an epileptogenic eﬀect. Recent evidence has provided
somehow contractor results. However, it is possible that
the apparent discrepancy between reports resides in the
terminology used to indicate the anatomical location of cells
and their quantiﬁcation. For instance, WBC brain invasion
was considered to occur even when a small number of
WBCs (∼1 cells/10mm2 of brain tissue) were found in the
parenchyma of epileptic human brains [33]. Our recent
data showed WBC accumulation mainly at the intra- and
perivascular compartments of the BBB in rodent model of
seizures and brains resected from epileptic subjects [20].
Moreover, when detected in the brain parenchyma, WBC
presence was limited to a speciﬁc subpopulation [39]. In
particular, granulocytes appeared transiently in rat brain
during epileptogenesis while monocytes/macrophages were
presentinthehippocampusuntilchronicseizuresdeveloped.
B- and T-lymphocytes and NK cells were negligible [39].
The presence of brain WBC also depended on the model of
seizure used. In general, it appears that a limited number of
WBCs home into the brain parenchyma, while most of the
WBCs are segregated to the perivascular BBB space. This is
in agreement with the fact that WBC vascular extravasation
understerileconditions(e.g.,absenceofpathogensasinmost
of the epilepsies) is an uncommon event. The possibility also
exists that WBC brain extravasation could be a reversible
event. In other words, it might be that cells “extravasate” and
then rapidly return into the blood stream. However, further
studies are needed to rule out this possibility. Nevertheless,
activated intravascular T-cells and granulocytes/monocytes
can produce proinﬂammatory factors that, upon reaching
the brain, could stimulate microglia and astrocytes causing
a local inﬂammatory response.
While WBC brain inﬁltrates are found in selected seizure
disorders where a clear antigenic component is present
(e.g., Rasmussen’s encephalitis, [40, 41]), we now propose
immunologic mechanisms of seizures applicable to a larger
number of epilepsies where autoimmunity is not present.
In other words, we suggest that, upon activation, WBCs act
at the BBB and reside in the proximity of the vasculature
without further entry into the brain parenchyma. Under
these circumstances, the endpoint facilitating seizures is
BBB damage regardless of subsequent WBC involvement.
Whether the perivascular homing of leukocytes will lead to
a more robust disruption of the BBB is possible but not
yet certain. This hypothesis stems from the fact that the
majority of seizure disorders are not associated with any
brain immunological signature, therefore “no brain” needs
to be identiﬁed and “neutralized” by the WBCs.
6. Restoring CerebrovascularIntegrityto
Prevent or Reduce Seizures
Given the considerations listed above, it becomes plausible
that BBB repair may be of antiseizure value. If BBB damage
promotes seizures, then prophylactic control of the events
leading to cerebrovascular failure should be eﬀective in pre-
venting or reducing seizures. Preservation of BBB integrity
may represent a complementary pharmacological approach
to the use of neuron-targeting AEDs. Glucocorticosteroids
(GCs), acting on the classic proinﬂammatory target and on
the cerebrovasculature, may thus become clinically useful
in preventing or reducing seizure occurrence (Figure 2 and
[21]).
We have recently obtained evidence supporting the
eﬀectiveness of adjunctive GCs treatment in children with
intractable epilepsy; we intentionally excluded those syn-
dromes known to be responsive to GCs and ACTH (L-G, L-
K, West or Rasmussen’s). GCs were beneﬁcial regardless of
the pathology and epileptic syndrome (Figure 2(c)). Similar
results were obtained using the pilocarpine model of status
epilepticus. We found that BBB integrity was preserved in
rats pretreated with anti-inﬂammatory agents [21]. Pre-
liminary results also showed that FLAIR hyperintensities6 Cardiovascular Psychiatry and Neurology
were attenuated in patients who responded to CG therapy,
suggesting that FLAIR is a surrogate radiologic index of BBB
damage (Figure 2(b)). A comprehensive study needs to be
performed in order to prove this.
The eﬃcacy of glucocorticosteroids in reducing drug-
resistant seizures remains, however, controversial. A Co-
chrane review suggests that steroids lack eﬃcacy [42]. The
latter study was based on a relatively small population of
subjects and derived from meta-analysis of a single trial.
Moreover, only ACTH was used, leaving out the use of com-
monly prescribed corticosteroids. In contrast, recent reports
have suggested the eﬃcacy of add-on glucocorticosteroids
in pediatric forms of epilepsy [43–46]. While no conclusive
studies are yet available, our recent published data [21]a n d
preliminary data in Figure 2 provided an indication of the
eﬃcacy of glucocorticosteroids in drug-resistant pediatric
seizures. We would also like to underscore that BBB damage
is observed independently of the species and the type of
seizures. BBB damage, as evaluated by albumin leakage,
is comparable regardless of means to induce seizures [20,
23, 47, 48]. Thus, if BBB failure is a trigger of chronic
as well as spontaneous, unprovoked, or iatrogenic seizures
then BBB repair may impact seizure burden regardless
of whether therapy is applied prophylactically or after
epileptogenesis is completed. Moreover, BBB damage during
epileptogenesis was found and was similar to BBB damage
observed in acute animal experiments or chronic patient
samples [20, 23, 47, 48].
7.DoWeNeedBetterExperimentalModelsto
DevelopBetterAEDs?
While all epilepsies are characterized by recurrent seizures,
profound etiological and pathophysiological diﬀerences exist
between them. These diﬀerences are often overlooked when
planning laboratory experiments. Experimental models of
epilepsy were originally created as drug screening tools,
and a reproducible number of seizures were therefore a
desirable goal. The use of these experimental models has
then been expanded to the understanding of mechanisms of
epileptogenesis and drug resistance. This leap has reduced
a variety of clinical epileptic syndromes to a few simplistic
models, disregarding the complex actuality of the epilepsies.
The question remains of how to develop an appropriate
experimental model able to mimic a speciﬁc epileptic
syndrome. Basic research relies on models of epilepsy
characterizedbyarapidonsetofgeneralizedseizures,leading
over time to spontaneous seizures. While these models
have generated important mechanistic insights of neuronal
transmission, basic science research needs to generate better
models to bring the development of new therapeutic options
onto a more clinically applicable level.
There are several clinically relevant models of neonatal
brain disease spanning from rodent models with genetic
defects or k.o. animals, models of epigenetic inheritance,
or models based on insertion of chromosomal material.
Teratogen exposure (drugs and/or environmental poisons),
maternal trauma, infection, and stroke are all factors that
might interfere with the normal progression of brain
development and give rise to aberrant patterns of cortical
structure.Acquiredcorticaldysplasiaappearstoresultfroma
progressive process (i.e., that may continue beyond the time
of insult), aﬀecting not only the primary region of lesion but
also surrounding “normal” tissue [49, 50].
Malformations of cortical development (MCD) are often
observed in clinical cases of drug-resistant epilepsy. Dys-
plastic regions are characterized by aberrant neuronal and
vascular architecture. Brain regions aﬀected by neurovas-
cular dysplasia have a lower seizure threshold compared
to normal brain [51–55]. While cortical dysplasia is a
common clinical correlate of earlyonset epilepsies, it is
diﬃcult to study the basic mechanisms linking dysplastic
lesions to epileptogenesis in human tissue. Models such as
the methylazoxymethanol (MAM) exposed rat were until
recently believed to cause MCD by a neurotoxic action.
MAM is a DNA alkylating agent. Injection (i.p.) of MAM
acetate into pregnant rats at day 14/15 of gestation (E14,
E15) exposes the fetuses to an agent that disrupts cell
proliferation at a time when neocortical and hippocampal
neurons and glia are being formed [56, 57]. The most
salient result of this manipulation is cortical thinning and
the generation of cortical heterotopias. A number of labo-
ratories have shown that MAM animals have lower seizure
thresholds than normal controls in response to a variety
of epileptogenic agents (ﬂurothyl, hyperthermia, kindling,
etc.; [58]). Studies have also suggested that these animals
have behavioral impairments [59]. The main pathology that
MAM recapitulates is microcephaly [60].
Recent ﬁndings, however, have shown a remarkable
toxicity of MAM towards endothelial cells and presence of
dimorphic and leaky BBB vessels [56]. In this scenario the
signiﬁcance of BBB damage does not only refer to iatrogenic
manipulation or traumatic events, but rather expands to var-
iouspathologicalchangesleadingtolossoffundamentalBBB
features, including selective permeability. In many ways, this
is conceptually analogous to “membrane integrity” in cells,
where small damage to membrane lipids may compromise a
variety of cellular functions. Recently it has been shown that
the toxins thalidomide (THAL) or MAM causes postnatal
brain maldevelopment and hyperexcitability associated to
abnormal vascular trunks [61]( Figure 3). In addition to
seizures, prenatal exposure to THAL, valproic acid alone, or
in combination with other agents [49]p r o d u c e sas p e c t r u m
of psychiatric and behavioral traits that are consistent with
the clinical presentation of neonatal seizures and subsequent
development of life-long neurological diseases. Why this
occurs is not fully understood, but our previous and current
results suggest that THAL and MAM, given at E15, (1) cause
a transient reduction of VEGF signaling resulting in limited
angiogenic potential at a time when cortical development is
maximal, and (2) aborted angiogenesis results in persistence
of abnormal vascular proﬁles [49, 61, 62], leaky BBB vessels
causing brain edema at birth, increased expression of water
channels, and decreased expression and function of BBB
tight junctions [49, 61, 62]; (3) the combined eﬀects of
edema and BBB leakage lead to improper development and
positioning of parenchymal brain cells (Figure 3), which,
ﬁnally, may cause seizures and permanent brain rewiring.Cardiovascular Psychiatry and Neurology 7
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Figure 3: Leakage of the BBB is associated with neonatal seizures. (a) Summary of the neurovascular changes induced by prenatal exposure
to MAM and/or THAL. (b) Seizures in neonatal THAL-MAM rats displayed on a joint time-frequency plot. Note also the traces recorded
by the scalp electrode. (c) Loss of selective BBB permeability is associated to brain edema and hemispheric asymmetry in THAL-MAM rats.
Red arrows point to region of disrupted cytoarchitecture due to vascular edema. (c1) FITC-albumin is used to indicate loss of BBB integrity.
Remarkably, in a subset of THAL-MAM new born rats,
epileptic ﬁts were recorded (Figure 3).
8. FinalRemarks
The BBB has been historically studied as a “pharmacoki-
netic” obstacle to brain drug delivery. However, cerebrovas-
cularfailurehasbeenrecentlyproposedtohaveanetiological
role in brain diseases that have been traditionally considered
neuronal in nature, among all seizure disorders. Based on
available evidence, we discussed the role of BBB failure
in the initiation and sustaining of seizures and epilepsies
and discussed whether a realistic clinical opportunity for
BBB drugs exists. Evidence suggests that such a clinical
opportunity does exist for drug-resistant forms of epilepsy,
where traditional neuronal AEDs fail to control seizure,
allowing for a complementary cerebrovascular therapeutic
option.
Acknowledgments
Support is by R01 NS060881 (to AJ), the Cleveland Clinic-
Swedish Satellite Laboratory Feasibility Project, Federal
Appropriation Washington State and R01 NS43284, R01
NS38195, R21 HD057256 to D. Janigro.
References
[1] G. A. Grant and D. Janigro, “The blood-brain barrier,”
in Youmans Neurological Surgery, H. R. Winn, Ed., vol. 1,
Saunders, Philadelphia, Pa, USA, 2010.
[2] N. J. Abbott, “Astrocyte-endothelial interactions and blood-
brain barrier permeability,” Journal of Anatomy, vol. 200, no.
6, pp. 629–638, 2002.
[3] N. J. Abbott, L. Ronnback, and E. Hansson, “Astrocyte-
endothelial interactions at the blood-brain barrier,” Nature
Reviews Neuroscience, vol. 7, no. 1, pp. 41–53, 2006.8 Cardiovascular Psychiatry and Neurology
[4] B. V. Zlokovic, “The Blood-Brain Barrier in Health and
Chronic Neurodegenerative Disorders,” Neuron, vol. 57, no. 2,
pp. 178–201, 2008.
[5] C. Ghosh, J. Gonzalez-Martinez, M. Hossain et al., “Pattern
of P450 expression at the human blood-brain barrier: roles of
epileptic condition and laminar ﬂow,” Epilepsia, vol. 51, no. 8,
pp. 1408–1417, 2010.
[6] S. M. Sisodiya, W. R. Lint, B. N. Harding, M. V. Squier, and M.
Thom,“Drugresistanceinepilepsy:humanepilepsy,”Novartis
Foundation Symposium, vol. 243, pp. 167–179, 2002.
[7] S. M. Sisodiya, “Mechanisms of antiepileptic drug resistance,”
Current Opinion in Neurology, vol. 16, no. 2, pp. 197–201,
2003.
[8] N. A. Oberheim, T. Takano, X. Han et al., “Uniquely hominid
features of adult human astrocytes,” Journal of Neuroscience,
vol. 29, no. 10, pp. 3276–3287, 2009.
[9] P. J. Magistretti and L. Pellerin, “Cellular basis of brain energy
metabolism and their relevance to brain imaging-evidence for
a prominent role for astrocytes,” Cerebral Cortex, vol. 5, pp.
301–306, 1995.
[10] N. Marchi, P. Rasmussen, M. Kapural et al., “Peripheral mark-
ers of brain damage and blood-brain barrier dysfunction,”
Restorative Neurology and Neuroscience, vol. 21, no. 3-4, pp.
109–121, 2003.
[11] N.Marchi,M.Cavaglia,V.Fazio,S.Bhudia,K.Hallene,andD.
Janigro, “Peripheral markers of blood-brain barrier damage,”
Clinica Chimica Acta, vol. 342, no. 1-2, pp. 1–12, 2004.
[12] A. A. Kanner, N. Marchi, V. Fazio et al., “Serum S100β:a
noninvasive marker of blood-brain barrier function and brain
lesions,” Cancer, vol. 97, no. 11, pp. 2806–2813, 2003.
[13] M. Kapural, L. Krizanac-Bengez, G. Barnett et al., “Serum S-
100β as a possible marker of blood-brain barrier disruption,”
Brain Research, vol. 940, no. 1-2, pp. 102–104, 2002.
[14] G. A. Grant and D. Janigro, “The blood-brain barrier,” in
Youmans Neurological Surgery, H. R. Winn, Ed., vol. 1, pp.
153–174, Saunders, Philadelphia, Pa, USA, 2004.
[15] A. Korn, H. Golan, I. Melamed, R. Pascual-Marqui, and
A. Friedman, “Focal cortical dysfunction and blood-brain
barrierdisruptioninpatientswithpostconcussionsyndrome,”
Journal of Clinical Neurophysiology, vol. 22, no. 1, pp. 1–9,
2005.
[16] R. H. Schmidt and M. S. Grady, “Regional patterns of blood-
brain barrier breakdown following central and lateral ﬂuid
percussion injury in rodents,” Journal of Neurotrauma, vol. 10,
no. 4, pp. 415–430, 1993.
[17] R. A. Kroll and E. A. Neuwelt, “Outwitting the blood-brain
barrier for therapeutic purposes: osmotic opening and other
means,” Neurosurgery, vol. 42, no. 5, pp. 1083–1100, 1998.
[18] C. Fieschi, G. L. Lenzi, and E. Zanette, “Eﬀects on EEG of
the osmotic opening of the blood-brain barrier in rats,” Life
Sciences, vol. 27, no. 3, pp. 239–243, 1980.
[19] N. Marchi, L. Angelov, T. Masaryk et al., “Seizure-promoting
eﬀect of blood-brain barrier disruption,” Epilepsia, vol. 48, no.
4, pp. 732–742, 2007.
[20] N. Marchi, Q. Teng, C. Ghosh et al., “Blood-brain barrier
damage, but not parenchymal white blood cells, is a hallmark
of seizure activity,” Brain Research, vol. 1353, pp. 176–186,
2010.
[21] N. Marchi, A. Batra, Q. Fan et al., “Antagonism of peripheral
inﬂammation prevents status epilepticus,” Neurobiology of
Disease, vol. 33, no. 2, pp. 171–271, 2009.
[22] V. Rigau, M. Morin, M. C. Rousset et al., “Angiogenesis is
associated with blood-brain barrier permeability in temporal
lobe epilepsy,” Brain, vol. 130, no. 7, pp. 1942–1956, 2007.
[23] E. Seiﬀert, J. P. Dreier, S. Ivens et al., “Lasting blood-
brain barrier disruption induces epileptic focus in the rat
somatosensory cortex,” Journal of Neuroscience, vol. 24, no. 36,
pp. 7829–7836, 2004.
[ 2 4 ]E .A .V a nV l i e t ,A .S .d aC o s t a ,S .R e d e k e r ,R .V a nS c h a i k ,E .
Aronica, and J. A. Gorter, “Blood-brain barrier leakage may
lead to progression of temporal lobe epilepsy,” Brain, vol. 130,
no. 2, pp. 521–534, 2007.
[25] V. Alvarez, P. Maeder, and A. O. Rossetti, “Postictal blood-
brainbarrierbreakdownoncontrast-enhancedMRI,” Epilepsy
and Behavior, vol. 17, no. 2, pp. 302–303, 2010.
[26] C. Amato, M. Elia, S. A. Musumeci, P. Bisceglie, and M.
Moschini, “Transient MRI abnormalities associated with
partial status epilepticus: a case report,” European Journal of
Radiology, vol. 38, no. 1, pp. 50–54, 2001.
[27] M.G.Lansberg,M.W .O’Brien,A.M.N orbash,M.E.M oseley ,
M. Morrell, and G. W. Albers, “MRI abnormalities associated
with partial status epilepticus,” Neurology, vol. 52, no. 5, pp.
1021–1027, 1999.
[28] K. M. Tan, J. W. Britton, J. R. Buchhalter et al., “Inﬂuence
of subtraction ictal SPECT on surgical management in focal
epilepsy of indeterminate localization: a prospective study,”
Epilepsy Research, vol. 82, no. 2-3, pp. 190–193, 2008.
[29] W. A. Hauser, “Epidemiology of acute symptomatic seizures,”
in Epilepsy: A Comprehensive Textbook,G .E n g e la n dT .A .
Pedley, Eds., pp. 71–75, Lippincott Williams and Wilkins,
Philadelphia, Pa, USA, 2008.
[30] E.ObyandD.Janigro,“Theblood-brainbarrierandepilepsy,”
Epilepsia, vol. 47, no. 11, pp. 1761–1774, 2006.
[31] S. Ivens, D. Kaufer, L. P. Flores et al., “TGF-β receptor-
mediated albumin uptake into astrocytes is involved in
neocortical epileptogenesis,” Brain, vol. 130, no. 2, pp. 535–
547, 2007.
[32] A. Vezzani and T. Granata, “Brain inﬂammation in epilepsy:
experimental and clinical evidence,” Epilepsia, vol. 46, no. 11,
pp. 1724–1743, 2005.
[33] P. F. Fabene, G. N. Mora, M. Martinello et al., “A role
for leukocyte-endothelial adhesion mechanisms in epilepsy,”
Nature Medicine, vol. 14, no. 12, pp. 1377–1383, 2008.
[34] G. Akhan, F. Andermann, and M. J. Gotman, “Ulcerative
colitis, status epilepticus and intractable temporal seizures,”
Epileptic Disorders, vol. 4, no. 2, pp. 135–137, 2002.
[35] Z. L. Chen and S. Strickland, “Neuronal death in the
hippocampus is promoted by plasmin-catalyzed degradation
of laminin,” Cell, vol. 91, no. 7, pp. 917–925, 1997.
[36] N. Marchi, E. Oby, N. Fernandez et al., “In vivo and in vitro
eﬀects of pilocarpine: relevance to ictogenesis,” Epilepsia, vol.
48, no. 10, pp. 1934–1946, 2007.
[37] R. Scheid and N. Teich, “Neurologic manifestations of ulcera-
tive colitis,” European Journal of Neurology, vol. 14, no. 5, pp.
483–492, 2007.
[38] S. Bauer, M. K¨ oller, S. Cepok et al., “NK and CD4+ T cell
changes in blood after seizures in temporal lobe epilepsy,”
Experimental Neurology, vol. 211, no. 2, pp. 370–377, 2008.
[39] T. Ravizza, B. Gagliardi, F. No´ e, K. Boer, E. Aronica, and A.
Vezzani, “Innate and adaptive immunity during epileptoge-
nesis and spontaneous seizures: evidence from experimental
models and human temporal lobe epilepsy,” Neurobiology of
Disease, vol. 29, no. 1, pp. 142–160, 2008.
[40] T. Granata, G. Gobbi, R. Spreaﬁco et al., “Rasmussen’s
encephalitis: early characteristics allow diagnosis,” Neurology,
vol. 60, no. 3, pp. 422–425, 2003.
[41] T. Granata, “Rasmussen’s syndrome,” Neurological Sciences,
vol. 24, no. 4, pp. S239–S243, 2003.Cardiovascular Psychiatry and Neurology 9
[42] N. A. Gayatri, C. D. Ferrie, and H. Cross, “Corticosteroids
including ACTH for childhood epilepsy other than epileptic
spasms,” Cochrane Database of Systematic Reviews,n o .1 ,
article CD005222, 2007.
[43] T. Araki, H. Otsubo, Y. Makino et al., “Eﬃcacy of dexamath-
asone on cerebral swelling and seizures during subdural grid
EEG recording in children,” Epilepsia, vol. 47, no. 1, pp. 176–
180, 2006.
[44] R. Gupta and R. Appleton, “Corticosteroids in the man-
agement of the paediatric epilepsies,” Archives of Disease in
Childhood, vol. 90, no. 4, pp. 379–384, 2005.
[45] D. B. Sinclair, “Prednisone therapy in pediatric epilepsy,”
Pediatric Neurology, vol. 28, no. 3, pp. 194–198, 2003.
[46] H. Verhelst, P. Boon, G. Buyse et al., “Steroids in intractable
childhood epilepsy: clinical experience and review of the
literature,” Seizure, vol. 14, no. 6, pp. 412–421, 2005.
[47] N. Marchi, Q. Teng, M. T. Nguyen et al., “Multimodal inves-
tigations of trans-endothelial cell traﬃcking under condition
ofdisruptedblood-brainbarrierintegrity,”BMCNeuroscience,
vol. 11, article 34, 2010.
[48] E. Van Vliet, E. Aronica, S. Redeker et al., “Selective and
persistent upregulation of mdr1b mRNA and P-glycoprotein
in the parahippocampal cortex of chronic epileptic rats,”
Epilepsy Research, vol. 60, no. 2-3, pp. 203–213, 2004.
[49] Q. Y. Fan, S. Ramakrishna, N. Marchi, V. Fazio, K. Hallene,
and D. Janigro, “Combined eﬀects of prenatal inhibition of
vasculogenesis and neurogenesis on rat brain development,”
Neurobiology of Disease, vol. 32, no. 3, pp. 499–509, 2008.
[50] M. Marin-Padilla, “Perinatal brain damage, cortical reorgani-
zation (acquired cortical dysplasias), and epilepsy,” Advances
in Neurology, vol. 84, pp. 153–172, 2000.
[51] M. E. Calcagnotto, M. F. Paredes, and S. C. Baraban, “Hetero-
topic neurons with altered inhibitory synaptic function in an
animal model of malformation-associated epilepsy,” Journal of
Neuroscience, vol. 22, no. 17, pp. 7596–7605, 2002.
[52] N. Chevassus-Au-Louis, P. Congar, A. Represa, Y. Ben-Ari,
and J. L. Ga¨ ıarsa, “Neuronal migration disorders: heterotopic
neocortical neurons in ca1 provide a bridge between the
hippocampus and the neocortex,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 95, no.
17, pp. 10263–10268, 1998.
[53] N. Chevassus-Au-Louis, A. Raﬁki, I. Jorquera, Y. Ben-Ari, and
A. Represa, “Neocortex in the hippocampus: an anatomical
and functional study of CA1 heterotopias after prenatal
treatment with methylazoxymethanol in rats,” Journal of
Comparative Neurology, vol. 394, no. 4, pp. 520–536, 1998.
[54] N. Chevassus-au-Louis, I. Jorquera, Y. Ben-Ari, and A.
Represa, “Abnormal connections in the malformed cortex of
rats with prenatal treatment with methylazoxymethanol may
support hyperexcitability,” Developmental Neuroscience, vol.
21, no. 3–5, pp. 385–392, 1999.
[55] R. Matsumoto, M. Kinoshita, J. Taki et al., “In vivo epilep-
togenicity of focal cortical dysplasia: a direct cortical paired
stimulation study,” Epilepsia, vol. 46, no. 11, pp. 1744–1749,
2005.
[56] S. Bassanini, K. Hallene, G. Battaglia et al., “Early cerebrovas-
cular and parenchymal events following prenatal exposure to
the putative neurotoxin methylazoxymethanol,” Neurobiology
of Disease, vol. 26, no. 2, pp. 481–495, 2007.
[57] G. Battaglia, S. Pagliardini, L. Saglietti et al., “Neurogenesis
in cerebral heterotopia induced in rats by prenatal methyla-
zoxymethanol treatment,” Cerebral Cortex,v o l .1 3 ,n o .7 ,p p .
736–748, 2003.
[58] S. C. Baraban and P. A. Schwartzkroin, “Flurothyl seizure
susceptibility in rats following prenatal methylazoxymethanol
treatment,”EpilepsyResearch,vol.23,no.3,pp.189–194,1996.
[ 5 9 ]M .D iL u c a ,F .M e r a z z i ,P .N .E .D eG r a a ne ta l . ,“ S e l e c t i v e
alteration in B-50/GAP-43 phosphorylation in brain areas
of animals characterized by cognitive impairment,” Brain
Research, vol. 607, no. 1-2, pp. 329–332, 1993.
[60] C. Colacitti, G. Sancini, S. DeBiasi et al., “Prenatal methyla-
zoxymethanol treatment in rats produces brain abnormalities
with morphological similarities to human developmental
braindysgeneses,”JournalofNeuropathologyandExperimental
Neurology, vol. 58, no. 1, pp. 92–106, 1999.
[61] K. L. Hallene, E. Oby, B. J. Lee et al., “Prenatal exposure to
thalidomide,alteredvasculogenesis,andCNSmalformations,”
Neuroscience, vol. 142, no. 1, pp. 267–283, 2006.
[62] N. Marchi, G. Guiso, S. Caccia et al., “Determinants of drug
brain uptake in a rat model of seizure-associated malforma-
tionsofcorticaldevelopment,”NeurobiologyofDisease,vol.24,
no. 3, pp. 429–442, 2006.